Document Detail


Comparative safety and efficacy of auranofin and parenteral gold compounds: a review.
MedLine Citation:
PMID:  6426044     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The comparative safety and efficacy of the orally active gold compound, auranofin, and parenteral gold compounds, principally gold sodium thiomalate, are reviewed. No difference in efficacy was detected in eight of the 12 published studies which compared auranofin and gold sodium thiomalate. Two studies favoured auranofin and two gold sodium thiomalate. Other parenteral gold compounds appeared more effective than auranofin. Adverse reactions and withdrawal rate from parenteral gold was found to be 2-3 times greater than from auranofin. Withdrawals due to inefficacy were found to be higher for auranofin than for parenteral gold although the incidence of inefficacy in the parenteral gold treated population was lower than that reported in other series. The nature of side effects from the two treatments was noticeably different; lower bowel symptoms with auranofin, and mucocutaneous lesions with parenteral gold compounds. Significant laboratory index changes were uncommon with both treatments, proteinuria being the most usual reason for withdrawal. Again the incidence of proteinuria and other laboratory abnormalities was less in the parenteral gold group than previously reported. Auranofin is possibly as effective and is definitely safer than parenteral gold compounds, and allows for longer periods of treatment.
Authors:
R J Horton
Related Documents :
7150504 - Effect of pregnancy of cellular inflammation.
1751444 - (patho)physiological implications of chronic dietary sodium restriction during pregnanc...
7191744 - Phimosis in boys.
22912724 - Timed maternal melatonin treatment reverses circadian disruption of the fetal adrenal c...
7495784 - Maternal hla class ii allogenotypes are markers for the predisposition to fetal losses ...
20131324 - Effects of nicotine on pulmonary surfactant proteins a and d in ovine lung epithelia.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Scandinavian journal of rheumatology. Supplement     Volume:  51     ISSN:  0301-3847     ISO Abbreviation:  Scand. J. Rheumatol. Suppl.     Publication Date:  1983  
Date Detail:
Created Date:  1984-06-18     Completed Date:  1984-06-18     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0400360     Medline TA:  Scand J Rheumatol Suppl     Country:  SWEDEN    
Other Details:
Languages:  eng     Pagination:  100-10     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Inflammatory Agents / adverse effects,  therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Auranofin
Aurothioglucose / adverse effects,  analogs & derivatives*,  therapeutic use
Clinical Trials as Topic
Drug Evaluation
Gold / analogs & derivatives*
Gold Sodium Thiomalate / adverse effects,  therapeutic use*
Humans
Safety
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 12192-57-3/Aurothioglucose; 12244-57-4/Gold Sodium Thiomalate; 34031-32-8/Auranofin; 7440-57-5/Gold

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of the kinetics of parenteral and oral gold.
Next Document:  The pharmacological profile of auranofin, an orally active gold compound.